论文部分内容阅读
目的:探讨布拉氏酵母菌预防阿奇霉素序贯法治疗小儿肺炎支原体肺炎后继发腹泻的研究。方法:将2010年12月~2012年12月收治的158例肺炎支原体肺炎患儿随机分为预防组(80例)及对照组(78例),两组均给予阿奇霉素序贯治疗,预防组加用布拉氏酵母菌治疗。分别观察给药第1、3、5天时支原体肺炎继发腹泻的发生率及严重程度;采用粪便涂片染色观察两组继发腹泻患儿肠道菌群失调程度;观察两组不良反应。结果:腹泻发生率:第1天对照组为6.41%,预防组为2.5%,两组比较差异无统计学意义(χ2=1.107,P>0.05);第3天对照组为15.38%,预防组为6.25%,两组比较差异有统计学意义(χ2=3.917,P<0.05);第5天对照组为23.08%,预防组为7.5%,两组比较差异有统计学意义(χ2=5.088,P<0.05)。对照组及预防组无腹泻、轻型腹泻、重型腹泻的构成比较差异有统计学意义,预防组腹泻程度较轻(u=3.6192,P<0.05)。对照组及预防组Ⅰ度、Ⅱ度、Ⅲ度肠道菌群失调程度的构成比较差异有统计学意义,预防组肠道菌群失调程度较轻(u=2.262,P<0.05)。预防组患儿依从性较好,未见不良事件。结论:布拉氏酵母菌能改善小儿肺炎支原体肺炎继发腹泻患儿肠道菌群失调程度,减轻继发腹泻的严重程度,降低继发性腹泻的发生率。
Objective: To investigate the prevention of secondary bacterial diarrhea caused by Mycoplasma pneumoniae in children with sequential administration of B. Methods: 158 children with Mycoplasma pneumoniae pneumonia admitted from December 2010 to December 2012 were randomly divided into prevention group (n = 80) and control group (n = 78). Both groups were treated with azithromycin sequential therapy Treatment with Brachyerella. The incidence and severity of secondary diarrhea secondary to mycoplasma pneumonia were observed on days 1, 3 and 5, respectively. The degree of intestinal microflora in children with secondary diarrhea was observed by stool smear staining. Adverse reactions of the two groups were observed. Results: The incidence of diarrhea was 6.41% in the control group and 2.5% in the prevention group on the first day. There was no significant difference between the two groups (χ2 = 1.107, P> 0.05). On the third day, the control group was 15.38% (Χ2 = 3.917, P <0.05). On the fifth day, the control group was 23.08% and the prevention group was 7.5%. The difference between the two groups was statistically significant (χ2 = 5.088, P <0.05). The control group and the prevention group had no diarrhea, mild diarrhea and severe diarrhea. There was significant difference in the constitution between the control group and the prevention group, and the diarrhea prevention group was less (u = 3.6192, P <0.05). There were significant differences in the composition of I, II, III degree intestinal flora in control group and prevention group, but the degree of gut flora in prevention group was less (u = 2.262, P <0.05). Prevention group children compliance is good, no adverse events. Conclusion: Brachyspira can improve the intestinal flora of children with secondary diarrhea due to Mycoplasma pneumoniae pneumonia, reduce the severity of secondary diarrhea and reduce the incidence of secondary diarrhea.